Ge Long Hui·2025-09-22 09:46Core Insights - Pfizer is nearing a $7.3 billion acquisition of weight-loss company Metsera, with an initial cash offer of $47.50 per share, potentially increasing to $73 billion based on performance milestones, representing a 110% premium over Metsera's last closing price of $33.32 [1] Company Summary - Metsera's stock surged by approximately 50% in pre-market trading, reflecting investor optimism regarding the acquisition [1] - The acquisition will provide Pfizer access to Metsera's weight-loss injection MET-233i, which has shown promising results in early trials, enabling patients to lose up to 8.4% of their weight in 36 days [1] - MET-233i may offer a competitive advantage over existing products from market leaders like Novo Nordisk and Eli Lilly by reducing the frequency of administration from weekly to monthly [1] Market Context - The weight-loss drug market is valued in the billions, indicating significant growth potential for Pfizer post-acquisition [1] - Metsera's market capitalization was reported at $3.5 billion prior to the acquisition announcement, highlighting the substantial premium Pfizer is willing to pay [1]